Evidence map›Paper›PMID 41850705›Full record

ArticleGut2026

Targeting lipid droplets in the management of MASLD.

Sepideh Mikaeeli, David E Cohen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sepideh MikaeeliMedicine/Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
David E CohenMedicine/Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA david.cohen@csmc.edu.ORCID http://orcid.org/0000-0001-9827-6926

Funding

Phospholipid-Mediated Metabolic Control in the Pathogenesis of NAFLDR01DK056626 · NIDDK · YESHIVA UNIVERSITY · PI COHEN, DAVID E. · 2000 to 2024
$10.3M
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLDR01DK103046 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI DAVID E. COHEN, Susan J Hagen · 2015 to 2026
$7.6M
Regulation of Hepatic Lipid and Glucose Metabolism by Phosphatidylcholine TransfeR01DK048873 · NIDDK · YESHIVA UNIVERSITY · PI DAVID E. COHEN · 2003 to 2026
$5.8M
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver DiseaseR01DK133988 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI DAVID E. COHEN · 2023 to 2026
$2.0M
NIDDK NIH HHS R01 DK048873NIDDK NIH HHS R01 DK056626NIDDK NIH HHS R01 DK103046NIDDK NIH HHS R01 DK133988
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FATTY LIVERLIPIDSLIVERMETABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Identifiers

PMID41850705
PMCPMC13452472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.